Opinion|Videos|March 27, 2025

Use and Sequencing of Novel Treatments in NMIBC

Author(s)Chad A. Reichard, MD , Karim Chamie, MD, MSHS , R. Jonathan Henderson, MD

Experts discuss where they are using FDA-approved treatments for bacille Calmette-Guérin (BCG)–unresponsive patients in their practice, how they choose between these treatments, and how these advances have impacted the timing of radical cystectomy for patients.

Episodes in this series

EP. 1 Standard of Care and Intravesical Chemotherapy in NMIBC

EP. 1 Standard of Care and Intravesical Chemotherapy in NMIBC

EP. 2 BCG for treatment of NMIBC

EP. 2 BCG for treatment of NMIBC

EP. 3 Cystectomy in NMIBC

EP. 3 Cystectomy in NMIBC

EP. 4 New Intravesical Delivery Systems and TAR-200 in NMIBC

EP. 4 New Intravesical Delivery Systems and TAR-200 in NMIBC

EP. 5 TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP. 5 TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP. 6 TAR-200 Clinical Development Program in NMIBC

EP. 6 TAR-200 Clinical Development Program in NMIBC

EP. 7 Other Investigational Drug Delivery Systems in NMIBC

EP. 7 Other Investigational Drug Delivery Systems in NMIBC

EP. 8 Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP. 8 Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP. 9 FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP. 9 FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP. 10 Use and Sequencing of Novel Treatments in NMIBC

EP. 10 Use and Sequencing of Novel Treatments in NMIBC

EP. 11 Communication of Treatment Options for High-Risk NMIBC

EP. 11 Communication of Treatment Options for High-Risk NMIBC

EP. 12 Checkpoint Inhibitors for Treatment of NMIBC

EP. 12 Checkpoint Inhibitors for Treatment of NMIBC

EP. 13 Unmet Needs in NMIBC

EP. 13 Unmet Needs in NMIBC

EP. 14 Operationalizing TAR-200 and Other Delivery Systems in Practice

EP. 14 Operationalizing TAR-200 and Other Delivery Systems in Practice

EP. 15 Patient Communication and Treatment Adherence in NMIBC

EP. 15 Patient Communication and Treatment Adherence in NMIBC

EP. 16 Uptake of New Treatments in Urology Practice

EP. 16 Uptake of New Treatments in Urology Practice

EP. 17 Final Thoughts and Clinical Trials in NMIBC

EP. 17 Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

Where are you using these treatments in your practice, and how do you choose between them for BCG-unresponsive patients?
How have these advances changed the timing of radical cystectomy for patients?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Precision Medicine and Patient Selection in mHSPC

ByScott Sellinger, MD, FACS

August 20th 2026

Bringing POTOMAC Data Into Community Urology Practice for High-Risk NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Inside the POTOMAC Trial: Durvalumab Plus BCG for High-Risk NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBC